Study measures
In both arms, baseline demographics, HIV risk factors, and prior PrEP and PEP use were assessed at enrolment. For endpoint ascertainment at 24 and 48 weeks of follow‐up in both arms, CHWs and research staff conducted community‐based rapid HIV testing and HIV RNA testing (Gene Xpert, Cepheid) and administered a structured survey on PrEP and PEP use (i.e. pill ingestion) and HIV risk over the past 6 months. Specifically, for each month, participants were asked to retrospectively, self‐report general HIV risk, any risk due to sex with a partner with HIV or unknown status, any use of PrEP pills and any use of PEP.